Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medigen BiotechnologyROCO:3176 +2.31%58 Days Payable is 37.00 as of Dec. 2025, which is 14% below its 10-year median of 42.96. GuruFocus rates ROCO:3176 with a GF Score™ of 58/100 and a GF Value™ of NT$49.63 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 701 Biotechnology companies, Medigen Biotechnology ranks worse than 77.46% on this metric.
Medigen Biotechnology Days Payable Historical Data
* Premium members only.
The historical data trend for Medigen Biotechnology's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:3176 vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Medigen Biotechnology's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medigen Biotechnology Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Medigen Biotechnology's Days Payable distribution charts can be found below:
* The bar in red indicates where Medigen Biotechnology's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Medigen Biotechnology's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medigen Biotechnology (ROCO:3176) has a Days Payable of 37.00 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Medigen Biotechnology and its competitors. This is 14% below median its historical median of 42.96. Over the past decade, Medigen Biotechnology's Days Payable has ranged from 24.64 to 76.36. According to the industry distribution chart, Medigen Biotechnology ranks #543 out of 701 companies in the Biotechnology industry, placing it in the top 77.5%.
Is Medigen Biotechnology's Days Payable too high?
Medigen Biotechnology's current Days Payable of 37.00 is 14% below median its 10-year median of 42.96. Over the past 10 years, this metric has ranged from a low of 24.64 to a high of 76.36. The Biotechnology industry median Days Payable is 112.84. Medigen Biotechnology's value of 37.00 is 67.2% below this industry median. Based on the distribution chart, Medigen Biotechnology ranks #543 out of 701 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Medigen Biotechnology has a GF Score™ of 58/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medigen Biotechnology's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Medigen Biotechnology ranks #543 out of 701 companies for Days Payable. This places Medigen Biotechnology in the lower half of its industry. The industry median Days Payable is 112.84. Medigen Biotechnology's value of 37.00 is 67.2% below this benchmark. Historically, Medigen Biotechnology's own Days Payable has ranged from 24.64 to 76.36 over the past decade. While the company's 10-year median is 42.96 vs. the industry median of 112.84, Medigen Biotechnology has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 701 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medigen Biotechnology's current Days Payable of 37.00 is 67.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Medigen Biotechnology and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medigen Biotechnology's current Days Payable is 37.00, which is 14% below median its own 10-year median of 42.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medigen Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Medigen Biotechnology (ROCO:3176) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$49.63, compared to a current price of NT$35.40 — trading 28.7% below its estimated fair value. The current Days Payable is 37.00, which is 14% below median its 10-year median of 42.96 and 67.2% below the Biotechnology industry median of 112.84. Medigen Biotechnology's overall GF Score™ is 58/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Medigen Biotechnology (ROCO:3176), the current Days Payable is 37.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medigen Biotechnology (ROCO:3176) Overvalued in 2026?
Based on GuruFocus' analysis, Medigen Biotechnology stock appears to be undervalued.
The current stock price of NT$35.40 is trading 28.7% below its estimated GF Value™ of NT$49.63.
GuruFocus considers Medigen Biotechnology to be Modestly Undervalued.
Key valuation signals for ROCO:3176:
Days Payable: 37.00 (14% below median its 10-year median of 42.96)
GF Value™: NT$49.63 vs. price of NT$35.40 (28.7% below fair value)
Industry Position: 67.2% below the Biotechnology median (#543 of 701)
No single metric tells the full story. See the ROCO:3176 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medigen Biotechnology Corp is engaged in the research and development of new drugs and vaccines, cytotherapy, nucleic acid testing, and the production and sales of generic drugs, aesthetic medicine products and vaccine-related products. Its segments are the Nucleic acid department, the New drug and vaccine research and development segment, the Cytotherapy department, and the Generic drug, aesthetic medicine product and dietary supplement segment: responsible for production and sales and relevant services of western medicine, aesthetic medicine product, and dietary supplement. The majority of revenue is derived from generic drugs, aesthetic medicine products, and the dietary supplement segment. Geographically, it operates in Taiwan, China, and Other countries with revenue from Taiwan.
58GF Score
Get the complete analysis for ROCO:3176
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:3176 has been successfully added to your 
